Levi & Korsinsky, LLP announces that a CCXI class action lawsuit has been filed on behalf of investors who purchased ChemoCentryx, Inc. (CCXI) securities between November 26, 2019, and May 3, 2021. For more on the CCXI Lawsuit please contact us today.

According to the ChemoCentryx lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx’s New Drug Application (“NDA”) for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE CCXI CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in ChemoCentryx you have until July 6, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com